Business
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
WESTLAKE VILLAGE, Calif., May 18, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration (FDA), to oversee the clinical and regulatory strategy for GX-03, the Company’s investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1911,"height":772,"url":"https://media.zenfs.com/en/business-wire.com/96cc2a87e6a14db2d9d08b85a45e3ba4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y6rl6XJRjYGN7f0b704bwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4OA--/https://media.zenfs.com/en/business-wire.com/96cc2a87e6a14db2d9d08b85a45e3ba4","width":960,"height":388},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dvGYr8ARLgFyZGs0Tz0mqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI1OQ--/https://media.zenfs.com/en/business-wire.com/96cc2a87e6a14db2d9d08b85a45e3ba4","width":640,"height":259},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6bh3p5z_os0xpV4fe.e6Jg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA-/https://media.zenfs.com/en/business-wire.com/96cc2a87e6a14db2d9d08b85a45e3ba4","width":1200,"height":485}},"lazy":false},{"type":"text","content":"Dr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and Pipeline Indications ","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"WESTLAKE VILLAGE, Calif., May 18, 2026--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration (FDA), to oversee the clinical and regulatory strategy for GX-03, the Company’s investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis (eczema).","length":527,"tagName":"p"},{"type":"text","content":""Patients with inflammatory skin diseases still lack adequate treatment options, especially therapies that work well without causing significant systemic effects. GX-03 represents a differentiated approach focused on treating inflammation directly at the site of disease, potentially offering an important new localized treatment option," said Stephen Hahn. "This mission is deeply personal for me. My own family has struggled with atopic dermatitis, and I know firsthand how difficult and frustrating it can be. Throughout my career, I have remained focused on advancing therapies that are bo...